| 1 |
34877801 | Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. | 2022 Apr |
1 |
| 2 |
33935788 | Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling. | 2021 |
2 |
| 3 |
31494843 | The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. | 2020 Feb |
2 |
| 4 |
31164617 | Study Protocol for a Pilot, Open-Label, Prospective, and Observational Study to Evaluate the Pharmacokinetics of Drugs Administered to Patients during Extracorporeal Circulation; Potential of In Vivo Cytochrome P450 Phenotyping to Optimise Pharmacotherapy. | 2019 May 13 |
1 |
| 5 |
28686070 | Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19. | 2018 Jul |
1 |
| 6 |
27323294 | Simultaneous evaluation of substrate-dependent CYP3A inhibition using a CYP3A probe substrates cocktail. | 2016 Sep |
1 |
| 7 |
25940755 | Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. | 2015 Nov |
1 |
| 8 |
23071008 | Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes. | 2013 Feb |
2 |
| 9 |
22483397 | High-sensitivity liquid chromatography-tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. | 2012 May 1 |
1 |
| 10 |
22513143 | Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. | 2012 Jul 15 |
1 |
| 11 |
21198441 | An in vitro, high throughput, seven CYP cocktail inhibition assay for the evaluation of new chemical entities using LC-MS/MS. | 2011 Jan |
1 |
| 12 |
20002088 | Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. | 2009 Dec |
1 |
| 13 |
18634893 | Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. | 2008 Nov-Dec |
1 |
| 14 |
17452028 | Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma. | 2007 Jun 15 |
1 |
| 15 |
19356015 | Prioritization of clinical drug interaction studies using in vitro cytochrome P450 data: proposed refinement and expansion of the "rank order" approach. | 2007 Jan |
1 |
| 16 |
16857327 | Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. | 2006 Oct 10 |
1 |
| 17 |
16243813 | Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. | 2005 Oct 15 |
3 |
| 18 |
12751920 | Clinically important drug interactions with zopiclone, zolpidem and zaleplon. | 2003 |
1 |
| 19 |
11013424 | High-throughput cytochrome P450 inhibition screening via cassette probe-dosing strategy. IV. Validation of a direct injection on-line guard cartridge extraction/tandem mass spectrometry method for simultaneous CYP3A4, 2D6 and 2E1 inhibition assessment. | 2000 |
2 |
| 20 |
10460798 | Enhancement of cytochrome P-450 3A4 catalytic activities by cytochrome b(5) in bacterial membranes. | 1999 Sep |
1 |
| 21 |
8886602 | Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450. | 1996 Sep |
2 |
| 22 |
3196361 | Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. | 1988 Nov 15 |
5 |